-
1Academic Journal
المؤلفون: E. Denisova S., K. Laktionov K., T. Borisova N., Merab. Ardzinba S., A. Fedorova A., D. Yudin I., S. Magamedova S., Milada Ardzinba A., Е. Денисова С., К. Лактионов К., Т. Борисова Н., М. Ардзинба С., А. Федорова А., Д. Юдин И., С. Магамедова С.
المصدر: Meditsinskiy sovet = Medical Council; № 20 (2020); 188-193 ; Медицинский Совет; № 20 (2020); 188-193 ; 2658-5790 ; 2079-701X
مصطلحات موضوعية: non small cell lung cancer, radiation therapy, adenocarcinoma, abscopal effect, brain metastasis, case report, немелкоклеточный рак легкого, лучевая терапия, аденокарцинома, абскопальный эффект, метастатическое поражение, головной мозг, клинический случай
وصف الملف: application/pdf
Relation: https://www.med-sovet.pro/jour/article/view/5955/5440; Orth M., Lauber K., Niyazi M., Friedl A., Li M., Maihöfer C. et al. Current concepts in clinical radiation oncology. Radiat Environ Biophys. 2014;53(1):1–29. doi:10.1007/s00411-013-0497-2.; Mole R.H. Whole body irradiation; radiobiology or medicine? Br J Radiol. 1953;26(305):234–241. doi:10.1259/0007-1285-26-305-234.; Sklar G.N., Eddy H.A., Jacobs S.C., Kyprianou N. Combined antitumor effect of suramin plus irradiation in human prostate cancer cells: the role of apoptosis. J Urol. 1993;150(5 Pt 1):1526–1532. doi:10.1016/s0022-5347(17)35835-4.; Schaue D., McBride W.H. Opportunities and challenges of radiotherapy for treating cancer. Nat Rev Clin Oncol. 2015;12(9):527–540. doi:10.1038/nrclinonc.2015.120.; Reynders K., Illidge T., Siva S., Chang J.Y., De Ruysscher D. The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant. Cancer Treat Rev. 2015;41(6):503–510. doi:10.1016/j.ctrv.2015.03.011.; Demaria S., Ng B., Devitt M.L., Babb J.S., Kawashima N., Liebes L., Formenti S.C. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int J Radiat Oncol Biol Phys. 2004;58(3):862– 870. doi:10.1016/j.ijrobp.2003.09.012.; Trowell O.A. The sensitivity of lymphocytes to ionising radiation. J Pathol Bacteriol. 1952;64(4):687–704. doi:10.1002/path.1700640403.; Hoppe R.T., Fuks Z.Y., Strober S., Kaplan H.S. The long term effects of radiation of T and B lymphocytes in the peripheral blood after regional irradiation. Cancer. 1977;40(5):2071–2078. doi:10.1002/1097-0142(197711)40:53.0.co;2-v.; Cao M.D., Chen Z.D., Xing Y. Gamma irradiation of human dendritic cells influences proliferation and cytokine profile of T cells in autologous mixed lymphocyte reaction. Cell Biol Int. 2004;28(3):223–228. doi:10.1016/j.cellbi.2003.12.006.; Li N., Karin M. Ionizing radiation and short wavelength UV activate NF-kappaB through two distinct mechanisms. Proc Natl Acad Sci USA. 1998;95(22):13012–13017. doi:10.1073/pnas.95.22.13012.; Weichselbaum R.R., Liang H., Deng L., Fu Y.X. Radiotherapy and immunotherapy: a beneficial liaison? Nat Rev Clin Oncol. 2017;14(6):365–379. doi:10.1038/nrclinonc.2016.211.; Demaria S., Formenti S.C. Role of T lymphocytes in tumor response to radiotherapy. Front Oncol. 2012;2:95. doi:10.3389/fonc.2012.00095.; Younes E., Haas G.P., Dezso B., Ali E., Maughan R.L., Kukuruga M.A. et al. Local tumor irradiation augments the response to IL-2 therapy in a murine renal adenocarcinoma. Cell Immunol. 1995;165(2):243–251. doi:10.1006/cimm.1995.1211.; Filatenkov A., Baker J., Mueller A., Kenkel J., Ahn G., Dutt S. et al. Ablative Tumor Radiation Can Change the Tumor Immune Cell Microenvironment to Induce Durable Complete Remissions. Clin Cancer Res. 2015;21(16):3727–3739. doi:10.1158/1078-0432.CCR-14-2824.; Zeng J., See A., Phallen J., Jackson C., Belcaid Z., Ruzevick J. et al. Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. Int J Radiat Oncol Biol Phys. 2013;86(2):343–349. doi:10.1016/j.ijrobp.2012.12.025.; Vanpouille-Box C., Diamond J.M., Pilones K.A., Zavadil J., Babb J.S., Formenti S.C. et al. TGFβ Is a Master Regulator of Radiation Therapy-Induced Antitumor Immunity. Cancer Res. 2015;75(11):2232–2242. doi:10.1158/0008-5472.CAN-14-3511.; Rodriguez-Ruiz M.E., Rodriguez I., Garasa S., Barbes B., Solorzano J.L., Perez-Gracia J.L. et al. Abscopal Effects of Radiotherapy Are Enhanced by Combined Immunostimulatory mAbs and Are Dependent on CD8 T Cells and Crosspriming. Cancer Res. 2016;76(20):5994–6005. doi:10.1158/0008-5472.CAN-16-0549.; Shiraishi K., Ishiwata Y., Nakagawa K., Yokochi S., Taruki C., Akuta T. et al. Enhancement of antitumor radiation efficacy and consistent induction of the abscopal effect in mice by ECI301, an active variant of macrophage inflammatory protein-1alpha. Clin Cancer Res. 2008;14(4):1159–1166. doi:10.1158/1078-0432.CCR-07-4485.; Park S.S., Dong H., Liu X., Harrington S.M., Krco C.J., Grams M.P. et al. PD-1 Restrains Radiotherapy-Induced Abscopal Effect. Cancer Immunol Res. 2015;3(6):610–619. doi:10.1158/2326-6066.CIR-14-0138.; Lee Y., Auh S., Wang Y., Burnette B., Wang Y., Meng Y. et al. Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood. 2009;114(3):589–595. doi:10.1182/blood-2009-02-206870.; Yoshimoto Y., Suzuki Y., Mimura K., Ando K., Oike T., Sato H. et al. Radiotherapy-induced anti-tumor immunity contributes to the therapeutic efficacy of irradiation and can be augmented by CTLA-4 blockade in a mouse model. PLoS One. 2014;9(3):e92572. doi:10.1371/journal.pone.0092572.; Tang C., Welsh J.W., de Groot P., Massarelli E., Chang J.Y., Hess K.R. et al. Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells. Clin Cancer Res. 2017;23(6):1388–1396. doi:10.1158/1078-0432.CCR-16- 1432.; Wang R., Zhou T., Liu W., Zuo L. Molecular mechanism of bystander effects and related abscopal/cohort effects in cancer therapy. Oncotarget. 2018;9(26):18637–18647. doi:10.18632/oncotarget.24746.; Hamid O., Robert C., Daud A., Hodi S., Hwu W.J., Kefford R. et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013;369(2):134–144. doi:10.1056/NEJMoa1305133.; Gaipl U.S., Multhoff G., Scheithauer H., Lauber K., Hehlgans S., Frey B., Rödel F. Kill and spread the word: stimulation of antitumor immune responses in the context of radiotherapy. Immunotherapy. 2014;6(5):597–610. doi:10.2217/imt.14.38.; Habets T.H., Oth T., Houben A.W., Huijskens M.J., Senden-Gijsbers B.L., Schnijderberg M.C. et al. Fractionated Radiotherapy with 3 x 8 Gy Induces Systemic Anti-Tumour Responses and Abscopal Tumour Inhibition without Modulating the Humoral Anti-Tumour Response. PLoS One. 2016;11(7):e0159515. doi:10.1371/journal.pone.0159515.; Camphausen K., Moses M.A., Ménard C., Sproull M., Beecken W.D., Folkman J., O’Reilly M.S. Radiation abscopal antitumor effect is mediated through p53. Cancer Res. 2003;63(8):1990–1993. Available at: https://pubmed.ncbi.nlm.nih.gov/12702593.; de Araújo Farias V., O’Valle F., Lerma B.A., Ruiz de Almodóvar C., LópezPeñalver J.J., Nieto A. et al. Human mesenchymal stem cells enhance the systemic effects of radiotherapy. Oncotarget. 2015;6(31):31164–31180. doi:10.18632/oncotarget.5216.; Abuodeh Y., Venkat P., Kim S. Systematic review of case reports on the abscopal effect. Curr Probl Cancer. 2016;40(1):25–37. doi:10.1016/j. currproblcancer.2015.10.001.; Siva S., Callahan J., MacManus M.P., Martin O., Hicks R.J., Ball D.L. Abscopal [corrected] effects after conventional and stereotactic lung irradiation of non-small-cell lung cancer. J Thorac Oncol. 2013;8(8):e71-2. doi:10.1097/JTO.0b013e318292c55a.; Hamilton A.J., Seid J., Verdecchia K., Chuba P. Abscopal Effect after Radiosurgery for Solitary Brain Metastasis from Non-small Cell Lung Cancer. Cureus. 2018;10(12):e3777. doi:10.7759/cureus.3777.; Chuang C.H., Hsu J.F., Shen Y.T., Yang C.J. Regression of a metastatic lung mass after receiving whole brain irradiation: Can the abscopal effect cross the blood-brain barrier? Asia Pac J Clin Oncol. 2018;14(5):e548–e550. doi:10.1111/ajco.13051.; Okwan-Duodu D., Pollack B.P., Lawson D., Khan M.K. Role of radiation therapy as immune activator in the era of modern immunotherapy for metastatic malignant melanoma. Am J Clin Oncol. 2015;38(1):119–125. doi:10.1097/COC.0b013e3182940dc3.; Bitran J. The Abscopal Effect Exists in Non-small Cell Lung Cancer: A Case Report and Review of the Literature. Cureus. 2019;11(2):e4118. doi:10.7759/cureus.4118.; Liu Y., Dong Y., Kong L., Shi F., Zhu H., Yu J. Abscopal effect of radiotherapy combined with immune checkpoint inhibitors. J Hematol Oncol. 2018;11(1):104. doi:10.1186/s13045-018-0647-8.; Shi F., Wang X., Teng F., Kong L., Yu J. Abscopal effect of metastatic pancreatic cancer after local radiotherapy and granulocytemacrophage colony-stimulating factor therapy. Cancer Biol Ther. 2017;18(3):137–141. doi:10.1080/15384047.2016.1276133.; Deplanque G., Shabafrouz K., Obeid M. Can local radiotherapy and IL-12 synergise to overcome the immunosuppressive tumor microenvironment and allow “in situ tumor vaccination”? Cancer Immunol Immunother. 2017;66(7):833–840. doi:10.1007/s00262-017-2000-4.; https://www.med-sovet.pro/jour/article/view/5955
-
2Academic Journal
المؤلفون: E. Denisova S., M. Ardzinba S., K. Laktionov K., D. Yudin I., K. Sarantseva A., G. Shcherbakova V., N. Marinichenko V., Е. Денисова С., М. Ардзинба С., К. Лактионов К., Д. Юдин И., К. Саранцева А., Г. Щербакова В., Н. Мариниченко В.
المصدر: Meditsinskiy sovet = Medical Council; № 9 (2020); 258-264 ; Медицинский Совет; № 9 (2020); 258-264 ; 2658-5790 ; 2079-701X
مصطلحات موضوعية: Non small cell lung cancer, pneumonitis, Immune checkpoint inhibitors, PD-1, Nivolumab, case report, Immune related adverse events, немелкоклеточный рак легкого, ингибиторы контрольных точек иммунитета, пневмонит, ниволумаб, клинический случай, иммуноопосредованные нежелательные явления
وصف الملف: application/pdf
Relation: https://www.med-sovet.pro/jour/article/view/5743/5241; Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30. doi:10.3322/caac.21590.; Bareschino M.A., Schettino C., Rossi A., Maione P., Sacco P.C., Zeppa R., Gridelli C. Treatment of advanced non small cell lung cancer. J Thorac Dis. 2011;3(2):122–133. doi:10.3978/j.issn.2072-1439.2010.12.08.; Kim E.S., Hirsh V., Mok T., Socinski M.A., Gervais R., Wuet Y.L. et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet. 2008;372(9652):1809– 1818. doi:10.1016/S0140-6736(08)61758-4.; Iacono D., Chiari R., Metro G., Bennati C., Bellezza G., Cenci M. et al. Future options for ALK-positive non-small cell lung cancer. Lung Cancer. 2015;87(3):211–219. doi:10.1016/j.lungcan.2014.12.017.; Asahina H., Sekine I., Horinouchi H., Nokihara H., Yamamoto N., Kubota K. et al. Retrospective analysis of third-line and fourth-line chemotherapy for advanced non-small-cell lung cancer. Clin Lung Cancer. 2012;13(1):39–43. doi:10.1016/j.cllc.2011.06.008.; Stinchcombe T.E. The Use of EGFR Tyrosine Kinase Inhibitors in EGFR Wild-Type Non-Small-Cell Lung Cancer. Curr Treat Options Oncol. 2016;17(4):18. doi:10.1007/s11864-016-0394-4.; Doroshow D.B., Sanmamed M.F., Hastings K., Politi K., Rimm D.L., Chen L. et al. Immunotherapy in Non-Small Cell Lung Cancer: Facts and Hopes. Clin Cancer Res. 2019;25(15):4592–4602. doi:10.1158/1078-0432.CCR-18-1538.; Brahmer J., Reckamp K.L., Baas P., Crinò L., Eberhardt W.E., Poddubskaya E. et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell NonSmall-Cell Lung Cancer. N Engl J Med. 2015;373(2):123–135. doi:10.1056/NEJMoa1504627.; Borghaei H., Paz-Ares L., Horn L., Spigel D.R., Steins M., Ready N.E. et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med. 2015;373(17):1627–1639. doi:10.1056/NEJMoa1507643.; Postow M.A. Managing immune checkpoint-blocking antibody side effects. Am Soc Clin Oncol Educ Book. 2015;76–83. doi:10.14694/EdBook_AM.2015.35.76.; Gandhi L., Rodríguez-Abreu D., Gadgeel S., Esteban E., Felip E., Angelis F.D. et al. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. N Engl J Med. 2018;378(22):2078–2092. doi:10.1056/NEJMoa1801005.; Vokes E.E., Ready N., Felip E., Horn L., Burgio M.A., Antonia S.J. et al. Nivolumab versus docetaxel in previously treated advanced non-smallcell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases. Ann Oncol. 2018;29(4):959–965. doi:10.1093/annonc/mdy041.; Yasuda K., Tanaka T., Ishihara S., Otani K., Nishikawa T., Kiyomatsu T. et al. Intestinal perforation after nivolumab immunotherapy for a malignant melanoma: a case report. Surg Case Rep. 2017;3(1):94. doi:10.1186/s40792-017-0370-7.; Guan M., Zhou Y.P., Sun J.L., Chen S.C. Adverse events of monoclonal antibodies used for cancer therapy. Biomed Res Int. 2015;2015:428169. doi:10.1155/2015/428169.; Weber J.S., Yang J.C., Atkins M.B., Disis M.L. Toxicities of Immunotherapy for the Practitioner. J Clin Oncol. 2015;33(18):2092–2099. doi:10.1200/JCO.2014.60.0379.; Topalian S.L., Hodi F.S., Brahmer J.R., Gettinger S.N., Smith D.C., McDermott D.F. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443–2454. doi:10.1056/NEJMoa1200690.; Nishino M., Giobbie-Hurder A., Hatabu H., Ramaiya N.H., Hodi F.S. Incidence of Programmed Cell Death 1 Inhibitor-Related Pneumonitis in Patients With Advanced Cancer: A Systematic Review and Meta-analysis. JAMA Oncol. 2016;2(12):1607–1616. doi:10.1001/jamaoncol.2016.2453.; Wang Y., Zhou S., Yang F., Qi X., Wang X., Guan X. et al. Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysis. JAMA Oncol. 2019;5(7):1008–1019. doi:10.1001/jamaoncol.2019.0393.; Toh C.K., Wong E.H., Lim W.T., Leong S.S., Fong K.M., Wee J. et al. The impact of smoking status on the behavior and survival outcome of patients with advanced non-small cell lung cancer: a retrospective analysis. Chest. 2004;126(6):1750–1756. doi:10.1378/chest.126.6.1750.; Bouros D., Hatzakis K., Labrakis H., Zeibecoglou K. Association of malignancy with diseases causing interstitial pulmonary changes. Chest. 2002;121(4):1278–1289. doi:10.1378/chest.121.4.1278.; De Velasco G., Je Y., Bossé D., Awad M.M., Ott P.A., Moreira R.B. et al. Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients [published correction appears in Cancer Immunol Res. 2018;6(4):498–499]. Cancer Immunol Res. 2017;5(4):312–318. doi:10.1158/2326-6066.CIR-16-0237.; Naidoo J., Wang X., Woo K.M., Iyriboz T., Halpenny D., Cunningham J. et al. Pneumonitis in Patients Treated With Anti-Programmed Death-1/ Programmed Death Ligand 1 Therapy [published correction appears in J Clin Oncol. 2017;35(22):2590]. J Clin Oncol. 2017;35(7):709–717. doi:10.1200/JCO.2016.68.2005.; Xia L., Liu Y., Wang Y. PD-1/PD-L1 Blockade Therapy in Advanced NonSmall-Cell Lung Cancer: Current Status and Future Directions. Oncologist. 2019;24(1):31–41. doi:10.1634/theoncologist.2019-IO-S1-s05.; Shao J., Wang C., Ren P., Jiang Y., Tian P., Li W. Treatment- and immunerelated adverse events of immune checkpoint inhibitors in advanced lung cancer. Biosci Rep. 2020;40(5):BSR20192347. doi:10.1042/BSR20192347.; Engel-Nitz N.M., Johnson M.P., Bunner S.H., Ryan K.J. Real-World Costs of Adverse Events in First-Line Treatment of Metastatic Non-Small Cell Lung Cancer. J Manag Care Spec Pharm. 2020;26(6):729–740. doi:10.18553/jmcp.2020.26.6.729.; https://www.med-sovet.pro/jour/article/view/5743